Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.
about
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuriaComplement in Lupus Nephritis: New PerspectivesEculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerationsPesg PNH diagnosis, follow-up and treatment guidelinesA systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura.An international consensus approach to the management of atypical hemolytic uremic syndrome in children.Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement.Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.Atypical Hemolytic Uremic Syndrome and Chronic Ulcerative Colitis Treated with Eculizumab.Complement in disease: a defence system turning offensiveNew milestones ahead in complement-targeted therapy.Meningococcal disease and the complement system.Paroxysmal nocturnal hemoglobinuriaParoxysmal nocturnal hemoglobinuria: a single Spanish center's experience over the last 40 yrComplement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuriaIncreased eculizumab requirements during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: case report and review of the literature.Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathyNetrin-1 Reduces Monocyte and Macrophage Chemotaxis towards the Complement Component C5a.Small-molecule factor D inhibitors targeting the alternative complement pathway.Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria.Therapeutic control of complement activation at the level of the central component C3.Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemiaPresentation and Management of Paroxysmal Nocturnal Hemoglobinuria: A Single-Center Experience.Blood consult: paroxysmal nocturnal hemoglobinuria and its complicationsDevelopment of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II.Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide.Combined inhibition of C5 and CD14 efficiently attenuated the inflammatory response in a porcine model of meningococcal sepsis.Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going.Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.New perspectives on the thrombotic complications of haemolysis.Update on paroxysmal nocturnal haemoglobinuria: on the long way to understand the principles of the disease.Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry.Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bed.Complementopathies.Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.
P2860
Q24193045-CEA0B86F-7518-4138-91FD-44C567E7FBFDQ26740491-D84C5598-8747-4C77-A0CC-45531CD5371CQ26740877-1FA3479D-F07F-4508-BACD-402E08096707Q27021868-99697684-203E-4C98-88E1-325630489743Q28661698-9914983E-CF21-4271-952E-DACA320C2E95Q33412325-6987DACE-2E83-49FB-A729-035BAFC5317FQ33412347-47E460E7-C677-4486-941B-F2EBDA85A6BDQ33421861-7A988E80-CE1A-4116-B5CC-FCFED923344EQ33423769-C6D3DA4B-1E7E-4B6E-AAE2-B82839988378Q33424274-D32740DD-09CC-46A5-BB99-CF3B1C287990Q33424946-26D715B2-8190-49B3-8044-A2B6037A9407Q33425610-FC255008-F591-4654-9532-790F56FC72D8Q33431908-80A67363-D8A4-400E-B62C-6575E7C3FBA1Q33432423-A32542E4-A63F-49E9-B63E-989CEA64F38CQ33602320-3062E64D-E160-4DF1-AF38-BF079073060AQ34376170-B6872FAB-0487-4B22-8DC8-504F5DC1F4F3Q34431429-29CF4B33-B279-4749-A36B-E8A9E25658C0Q34516330-4C43BD72-0F0F-45FE-A812-C39078C3FB80Q34603645-252F4311-039F-40A7-9FE6-51F186F3899EQ35155748-9B0CFF9D-CD27-4E79-ABD7-770763CDD285Q35877192-63C5DD21-9D32-43FC-9C46-D8EDD2E127EAQ36100438-36ABE178-2483-4F7E-A3A0-B359E483A52BQ36172936-70CA1BC1-639D-4961-AA08-9C3E6C18101CQ36187306-3A2C2071-E7C3-400C-8DD3-97D54E4BC4E9Q36363005-D41198AF-052A-4ADE-8280-062D3344108AQ36416292-606E72D7-3B0D-43B9-9FBC-9FB0036B845EQ36751227-D14CC7F5-C3EB-473A-BB90-A48CBE254DBEQ37235669-282334B2-00F1-4685-A740-4E50AFBB54FAQ37580829-93871AD4-57B7-4887-8BD1-550F4A9EC0FAQ37638781-231B6DC8-E95D-464F-9FEE-95FDB2B3AB17Q37668330-0E07C8DC-85A5-4DAE-9610-15F5FC3DBFA7Q37670073-3A201B0F-3D44-4E54-B140-459382B3F40EQ37724607-A49DF23D-6D3F-4DED-BD0E-E57A288E0F86Q38156229-5126A244-8902-4BC9-91F1-DB59F6DA59ABQ38259274-6EEBF73C-EA8C-45AF-8262-F05602CAD419Q38363645-30E56EA8-7112-4956-892C-2E13A3BFAFE5Q38658582-576D570D-D189-4C0A-A828-C3B8B26A1D95Q38998217-000FA909-6A6A-4111-AB93-BF992B354C5BQ39142842-8843F8A6-604C-4354-8433-4BCACBC1ECF3Q39554119-E37A96F1-DFCE-4EDA-8FF7-8BEF72E3F72F
P2860
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term safety and efficacy ...... mal nocturnal haemoglobinuria.
@en
Long-term safety and efficacy ...... mal nocturnal haemoglobinuria.
@en-gb
Long-term safety and efficacy ...... mal nocturnal haemoglobinuria.
@nl
type
label
Long-term safety and efficacy ...... mal nocturnal haemoglobinuria.
@en
Long-term safety and efficacy ...... mal nocturnal haemoglobinuria.
@en-gb
Long-term safety and efficacy ...... mal nocturnal haemoglobinuria.
@nl
prefLabel
Long-term safety and efficacy ...... mal nocturnal haemoglobinuria.
@en
Long-term safety and efficacy ...... mal nocturnal haemoglobinuria.
@en-gb
Long-term safety and efficacy ...... mal nocturnal haemoglobinuria.
@nl
P2093
P2860
P50
P356
P1476
Long-term safety and efficacy ...... mal nocturnal haemoglobinuria.
@en
P2093
Alexander Röth
Alvaro Urbano-Ispizua
Antonio M Risitano
Carlos de Castro
Hubert Schrezenmeier
Jaroslaw P Maciejewski
Jeffrey Szer
Jörg Schubert
Modupe O Elebute
Paul Browne
P2860
P356
10.1111/BJH.12347
P407
P577
2013-04-25T00:00:00Z